Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM326 in Moderate to Severe Asthma
CTR20260115Phase 3Active
- Sponsor
- Keymed Biosciences
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of CM326 in asthma, sponsored by Keymed Biosciences. Started Mar 2026; status: active.
02
Drugs
CM326
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20260115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260115.